StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$6.88−0.14 (-1.99%)

Close on Nov 18, 2026Market cap $249.69MP/E –Yield –

Evommune free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Evommune's free cash flow for the twelve months ending Sep 30, 2026 was -$91.00M. For fiscal 2025 it was -$76.68M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.68M–
FY2024Dec 31, 2024-$58.28M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$26.12M–
Q2 FY2026Jun 30, 2026-$20.50M–
Q1 FY2026Mar 31, 2026-$27.59M–
Q4 FY2025Dec 31, 2025-$16.80M–
Q3 FY2025Sep 30, 2025-$9.77M–
Q2 FY2025Jun 30, 2025-$26.21M–
Q1 FY2025Mar 31, 2025-$23.90M–
Q4 FY2024Dec 31, 2024-$18.51M–

More Evommune figures

See a number that looks wrong?